At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 25 enrolled
Drug / intervention
Personalized Vaccine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Safety and Feasibility Study of Personalized Immunotherapy in Adults With Advanced Cancers
In Brief
A Phase 1 clinical trial evaluating Personalized Vaccine and Pembrolizumab for Advanced Cancer. Completed, enrolled 25 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if it is possible to make and administer safely a 'personalized' vaccine to treat patients that have been diagnosed with advanced cancer and are not candidates for curative therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartJul 2018
Primary CompletionDec 2022
Study CompletionJan 2025
TodayJul 2026
First PostedJun 26, 2018
Enrollment StartJul 26, 2018
Primary CompletionDec 12, 2022
Study CompletionJan 27, 2025
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 8.0 years ago
Interventions
Personalized Vaccinedrug
Vaccine was constructed for each subject that express multiple candidate tumor-derived neoantigens. Administered intramuscular injection every 3 weeks.
Pembrolizumabdrug
Pembrolizumab was administered intravenous (IV) infusion every 3 weeks.